Abiopharma

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

New Form 424B2 - CITIGROUP INC <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001918704-26-023660 <b>Size:</b> 649 KB

Studio City International Holdings Limited Announces Unaudited Second Quarter 2026 Earnings

(99% Neutral) MONRO, INC. (MNRO) Files Form 8-K

New Form 424B2 - BARCLAYS BANK PLC <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001918704-26-023658 <b>Size:</b> 331 KB

New Form 424B4 - Silexion Therapeutics Corp <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001178913-26-004116 <b>Size:</b> 3 MB

New Form 424B2 - BARCLAYS BANK PLC <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001918704-26-023659 <b>Size:</b> 304 KB

New Form SCHEDULE 13G - REGENTIS BIOMATERIALS LTD. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001622627-26-000021 <b>Size:</b> 13 KB

(19% Negative) GRACE THERAPEUTICS, INC. (GRCE) Reports Q3 2026 Financial Results

NextPlat Reports 21% Sequential Quarterly Revenue Growth, 87% Reduction in Quarterly Net Loss to $144,000 and Record Gross Margin of Approximately 40%

Melco Resorts Announces Unaudited Second Quarter 2026 Earnings

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001213900-26-088855 <b>Size:</b> 2 MB

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

(30% Negative) VENU HOLDING CORP (VENU) Reports Q3 2026 Financial Results